Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
Abstract Aims High myocardial stiffness in heart failure with preserved ejection fraction (HFpEF) is attributed to comorbidity‐induced structural and functional remodelling through inflammation and oxidative stress affecting coronary microvascular endothelial cells and cardiomyocytes, which augments...
Main Authors: | Mariëlle Scheffer, Annet Driessen‐Waaijer, Nazha Hamdani, Jochem W.D. Landzaat, Nini H. Jonkman, Walter J. Paulus, Loek vanHeerebeek |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13055 |
Similar Items
-
Leukocyte count and the risk of adverse outcomes in patients with HFpEF
by: Zhaowei Zhu, et al.
Published: (2021-07-01) -
Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
by: Maria Barilli, et al.
Published: (2022-04-01) -
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01) -
Biomarker profiling for risk of future heart failure (HFpEF) development
by: Chris J. Watson, et al.
Published: (2021-02-01) -
Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
by: Leonie Grossekettler, et al.
Published: (2020-05-01)